Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis

Condition:   Plaque Psoriasis Interventions:   Biological: Secukinumab;   Radiation: nbUVB;   Biological: Secukinumab;   Biological: Secukinumab;   Biological: Secukinumab;   Drug: Calcipotriol;   Drug: Betamethasone Sponsor:   Novartis Pharmaceuticals Not yet recruiting - verified January 2017

Source: ClinicalTrials.gov - September 23, 2016 Category: Research Source Type: clinical trials